Abstracts tagged "Biomarkers"

Abstract Number: 1422 • 2019 ACR/ARP Annual Meeting
Reduction in CD4 TEMRA Cells and Its Association with DAS28 (CRP) < 2.6 Treatment Response with Abatacept in Patients with Early, ACPA+, DMARD-Naïve RA
Paul Emery¹, Yoshiya Tanaka ², Vivian Bykerk ³, Clifton Bingham ⁴, Thomas Huizinga ⁵, Gustavo Citera ⁶, Sean Connolly ⁷, Kuan-Hsiang Gary Huang ⁷, Yedid Elbez ⁸, Sumanta Mukherjee ⁷ and Roy Fleischmann ⁹, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, ²University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ³Hospital for Special Surgery, New York City, NY, ⁴Johns Hopkins University, Baltimore, MD, ⁵Leiden University Medical Center, Leiden, Netherlands, ⁶Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, ⁷Bristol-Myers Squibb, Princeton, NJ, ⁸Excelya, Boulogne-Billancourt, France, ⁹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: T-cell profiles are heterogeneous between individuals and consist of naïve T cells, memory T cells (including effector memory T cells [TEM] and central memory…
Abstract Number: 2432 • 2019 ACR/ARP Annual Meeting
Thymic Stromal Lymphopoietin (TSLP) as a Biomarker of Primary Sjögren’s Syndrome (pSS) and Related Lymphoma: Results in Independent Cohorts
Saviana Gandolfo¹, Cinzia Fabro ¹, Serena Colafrancesco ², Francesco Carubbi ³, Francesco Ferro ⁴, Elena Bartoloni ⁵, Efstathia Kapsogeorgou ⁶, Andreas Goules ⁶, Luca Quartuccio ¹, Roberta Priori ², Alessia Alunno ⁵, Guido Valesini ², Roberto Giacomelli ³, Roberto Gerli ⁵, Chiara Baldini ⁴, Athanasios Tzioufas ⁶ and Salvatore De Vita ¹, ¹Rheumatology Clinic, Udine University Hospital, Department of Medical Area, University of Udine, Udine, Italy, Udine, Italy, ²Rheumatology Unit, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Rome, Italy, Roma, Italy, ³Rheumatology Unit, Department of Biotechnological and Applied Clinical Science, School of Medicine, University of L'Aquila, L'Aquila, Italy, L'Aquila, Italy, ⁴Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, Pisa, Italy, ⁵Rheumatology Unit, Department of Medicine, University of Perugia, Perugia, Italy, Perugia, Italy, ⁶Department of Pathophysiology, Athens School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece
Background/Purpose: Thymic stromal lymphopoietin (TSLP) has been implicated in primary Sjögren’s syndrome (pSS) and related B-cell lymphoproliferation / lymphoma (NHL) by tissue studies on salivary…
Abstract Number: 534 • 2019 ACR/ARP Annual Meeting
CXCL13 Serum Levels and Circulating Follicular Helper T-Cells Decrease After Co-stimulation Blockade with Abatacept in Rheumatoid Arthritis
Silvia Piantoni¹, Francesca Regola ², Laura Andreoli ³, Angela Tincani ³ and Paolo Airò ⁴, ¹ASST Spedali Civili and University of Brescia, Brescia, Italy, ²Rheumatology and Clinical Immunology Unit, ASST Spedali Civili and University of Brescia, Brescia, Italy, Brescia, Italy, ³Rheumatology and Clinical Immunology, Spedali Civili and Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy, Brescia, Italy, ⁴UO Reumatologia e Immunologia Clinica, Spedali Civili di Brescia, Brescia, Italy, Brescia, Italy
Background/Purpose: CXCL13 chemokine, by interacting with CXCR5 receptor, attracts B-lymphocytes and CD4+CXCR5+ICOS+ follicular helper T-lymphocytes (THFs) in lymphoid follicles. In rheumatoid arthritis (RA) CXCL13 is…
Abstract Number: 1424 • 2019 ACR/ARP Annual Meeting
The Effect of HLA-DRB1 Risk Alleles (Shared Epitope) on Changes in Immune Cell Subsets and Disease Activity Following Treatment with Abatacept versus Adalimumab in Seropositive Biologic-Naïve Patients with Early, Moderate-to-Severe RA: Data from a Head-to-Head Single-Blinded Trial
Jane Buckner¹, Vivian Bykerk ², V. Michael Holers ³, S. Louis Bridges ⁴, William Rigby ⁵, Sheng Gao ⁶, Marleen Nys ⁷ and Neelanjana Ray ⁸, ¹Benaroya Research Institute, Seattle, WA, ²Hospital for Special Surgery, New York City, NY, ³University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Denver, ⁴University of Alabama at Birmingham, Birmingham, ⁵Dartmouth-Hitchcock Medical Center, Lebanon, ⁶Bristol-Myers Squibb, Princeton, NJ, ⁷Bristol-Myers Squibb, Braine L’Alleud, Belgium, ⁸Bristol-Myers Squibb, Princeton
Background/Purpose: Mechanistic differences between biologic DMARDs are poorly understood. Exploring these mechanisms includes assessing the role of HLA-DRB1 alleles containing the shared epitope (SE), which…
Abstract Number: 2558 • 2019 ACR/ARP Annual Meeting
Profiling of Gene Expression, Immune Cell Subtypes, and Circulating Protein Biomarkers in Systemic Lupus Erythematosus Patients Treated with the Selective Immunoproteasome Inhibitor, KZR-616
R Andrea Fan¹, Janet Anderl ¹, Brian Tuch ², Darrin Bomba ¹, Niti Goel ³ and Christopher Kirk ¹, ¹Kezar Life Sciences, South San Francisco, CA, ²Kezar Life Sciences, south san francisco, ³Kezar Life Sciences, Duke University School of Medicine, South San Francisco, CA
Background/Purpose: KZR-616 is a selective inhibitor of the immunoproteasome, the form of proteasome found predominantly in immune cells. In nonclinical studies, KZR-616 blocks acute production…
Abstract Number: 583 • 2019 ACR/ARP Annual Meeting
A Biomarker of Type VI Collagen Degradation (C6M) Is Associated with Changes in ASDAS MRI Measures of Inflammation in Patients with Axial Spondyloarthritis During TNF Inhibitor Therapy
Signe Holm Nielsen¹, Anne Bay-Jensen ², Mikkel Østergaard ³, Anne Siebuhr ⁴, Morten Karsdal ⁵, inge Juul Sørensen ⁶, Ulrich Weber ⁷, Anne Gitte Loft ⁸, Gina Kollerup ⁹, Gorm Thamsborg ⁹, Ole Rintek Madsen ¹⁰, Jakob Møller ¹¹ and Susanne Juhl Pedersen ¹², ¹Nordic Bioscience/Technical University of Denmark, Herlev, Denmark, ²Nordic Bioscience, Herlev, Denmark, ³Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark, ⁴Nordic Bioscience, Herlev, ⁵Nordic Bioscience, Copenhagen, Denmark, ⁶Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark, Glostrup, Denmark, ⁷Danish Hospital for Rheumatic Diseases, University Hospital of Southern Denmark, Sonderborg, Denmark, ⁸Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, Århus, Denmark, ⁹Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, Copenhagen, Hovedstaden, Denmark, ¹⁰Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, Copenhagen, Denmark, ¹¹Department of Radiology, Herlev and Gentofte University Hospital, Herlev, Denmark, Copenhagen, Denmark, ¹²Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, Copenhagen, Hovedstaden, Denmark
Background/Purpose: Axial spondyloarthritis (AxSpa) is characterized by inflammation in the sacroiliac joints and spine and associated with extracellular matrix (ECM) remodelling of affected tissues. Type…
Abstract Number: 1594 • 2019 ACR/ARP Annual Meeting
High Expression of CD38 on CD8 T Cells Predicts Increased Burden of Infections in Patients with SLE
Lama Mulki¹, Abel Suarez-Fueyo ², Eri Katsuyama ², Vasileios Kyttaris ² and George Tsokos ², ¹Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, ²Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
Background/Purpose: We have previously reported that CD38 gene expression in the peripheral blood T cell from patients with SLE is increased. CD8+CD38+ T cells have…
Abstract Number: 2637 • 2019 ACR/ARP Annual Meeting
Urine Complement Ba Levels During Flares of Renal Disease in Patients with ANCA-Associated Vasculitis
Salem Almaani¹, Christopher Toy ², Anna Levesque ², Lynn Fussner ¹, Alexa Meara ¹, Lianbo Yu ¹, David Cuthbertson ³, Simon Carette ⁴, Nader A. Khalidi ⁵, Curry L. Koening ⁶, Carol Langford ⁷, Carol A. McAlear ⁸, Larry Moreland ⁹, Christian Pagnoux ¹⁰, Philip Seo ¹¹, Antoine Sreih ¹², Steven Ytterberg ¹³, Paul Monach ¹⁴, Peter Merkel ¹², Brad Rovin ¹ and Dan Birmingham ¹⁵, ¹The Ohio State University Medical Center, Columbus, OH, ²Ohio State University, Columbus, OH, ³University of South Florida, Tampa, FL, ⁴Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, Canada, ⁵McMaster University, Hamilton, ON, Canada, ⁶University of Utah Hospital, Salt Lake City, UT, ⁷Cleveland Clinic, Cleveland, OH, ⁸University of Pennsylvania - VCRC Project Manager, Philadelphia, PA, ⁹University of Pittsburgh, PITTSBURGH, PA, ¹⁰Mount Sinai Hospital and University Health Network, Toronto, ON, Canada, ¹¹Johns Hopkins Medicine, Baltimore, MD, ¹²University of Pennsylvania, Philadelphia, PA, ¹³Mayo Clinic College of Medicine, Rochester, MN, ¹⁴Brigham and Women's Hospital, Boston, MA, ¹⁵The Ohio State University Medical Center, Columbus
Background/Purpose: The alternative complement pathway has been implicated in the pathogenesis of ANCA-associated vasculitis (AAV). Change in markers of complement activation within patients have not…
Abstract Number: 641 • 2019 ACR/ARP Annual Meeting
A Novel Method to Analyze Circulating Immune Complexes Predicts Disease Activity and Severity in Systemic Lupus Erythematosus and Rheumatoid Arthritis
Anders Bengtsson ¹, Helena Tyden ¹, Tiffany Pan ², J. Lee Nelson ³ and Christian Lood², ¹Lund University, Lund, Sweden, ²University of Washington, Seattle, ³Fred Hutchinson Cancer Research Center, Seattle
Background/Purpose: Circulating immune complexes (IC) are detectable in a variety of systemic inflammatory diseases, including rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), reflecting the…
Abstract Number: 1661 • 2019 ACR/ARP Annual Meeting
Circulating Cell Free DNA Released from Eosinophils Is a Practical Biomarker in Patients with Eosinophilic Granulomatosis with Polyangiitis
Teppei Hashimoto¹, Yuichi Yokoyama ², Tetsuya Furukawa ³, Takahiro Yoshikawa ³, Naoto Azuma ², Kohsuke Yoshida ⁴, Akira Hashiramoto ⁴ and Kiyoshi Matsui ³, ¹Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Kobe, Hyogo, Japan, ²Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan, ³Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan, ⁴Kobe University Graduate School of Health Sciences, Kobe, Hyogo, Japan
Background/Purpose: Fragmented cell-free DNA (cfDNA) is released into blood circulation as results of damage or death of peripheral blood cells as well as organ tissues,…
Abstract Number: 2848 • 2019 ACR/ARP Annual Meeting
Semiquantitative Assessment of Synovial Inflammation on US-Guided Synovial Membrane Biopsy Is Contingent to Disease Phase, Autoimmune Profile and Treatment Response in Rheumatoid Arthritis: Large Single Center Experience (SYNGem Cohort)
Stefano Alivernini¹, Barbara Tolusso ¹, Marco Gessi ², Maria Rita Gigante ¹, Luca Petricca ¹, Clara Di Mario ³, Simone Perniola ¹, Anna Laura Fedele ¹, Giusy Peluso ⁴, Laura Bui ², Annunziata Capacci ¹, Francesco Federico ², Gianfranco Ferraccioli ³ and Elisa Gremese ¹, ¹Division of Rheumatology - Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ²Division of Pathology - Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ³Institute of Rheumatology - Università Cattolica del Sacro Cuore, Rome, Italy, ⁴Division of Rheumatology - Fondazione Policlinico Universitario A. Gemelli IRCCS, Italy, Italy
Background/Purpose: Ultrasound (US)-guided minimally-invasive Synovial Tissue (ST) biopsy is a well tolerated procedure for basic and translational studies on chronic inflammatory joint diseases as Rheumatoid…
Abstract Number: 686 • 2019 ACR/ARP Annual Meeting
Association Between the Soluble Terminal Complement Complex C5b-9 (sC5b-9) and Signs of Active Kidney Disease in a Swiss SLE Cohort
Kristin Schmiedeberg ¹, Ruediger B. Mueller ², Thomas Neumann ¹, Ian Pirker ¹, Philipp Rein ³, Camillo Ribi ⁴, Andrea Rubbert-Roth ⁵, Michael Kirschfink ⁶, Reinhard Voll ⁷ and Johannes von Kempis¹, ¹Division of Rheumatology and Immunolog, Kantonsspital St. Gallen, St. Gallen, Sankt Gallen, Switzerland, ²Clinic of Rheumatology, Medical University Hospital Aarau, Aarau, Aargau, Switzerland, ³Division of Rheumatology and Immunolog, Kantonsspital St. Gallen, St.Gallen, Sankt Gallen, Switzerland, ⁴Service of Immunology and Allergy, Lausanne University Hospital and University of Lausanne, Lausanne, Vaud, Switzerland, ⁵Division of Rheumatology, Kantonsspital St. Gallen, St. Gallen, Sankt Gallen, Switzerland, ⁶Institute of Immunology, University of Heidelberg, Heidelberg, Germany, ⁷Division of Rheumatology and Clinical Immunology, Medical Centre - University of Freiburg, Freiburg, Germany
Background/Purpose: There is a lack of reliable biomarkers for disease activity in SLE. While C3a, an anaphylatoxin generated during of complement activation, could be predictive…
Abstract Number: 1694 • 2019 ACR/ARP Annual Meeting
Pharmacogenetics and Pharmacodynamics of Response to Apremilast in a Phase 3 Clinical Study in Subjects with Active Behçet’s Disease
Joseph Maranville¹, Irina Medvedeva ¹, Robert Yang ¹, Mindy Chen ², Lorraine (Ruoying) Fang ², Sandra Collazo ³, Shannon McCue ³, Marla Hochfeld ³ and Peter Schafer ³, ¹Celgene Corporation, Cambridge, MA, ²Celgene Corporation, Berkeley Heights, NJ, ³Celgene Corporation, Summit, NJ
Background/Purpose: This was an exploratory analysis of genetic polymorphisms, plasma biomarkers, and blood leukocytes with clinical response in the phase 3 clinical study CC-10004-BCT-002 (NCT02307513).Methods:…
Abstract Number: 2887 • 2019 ACR/ARP Annual Meeting
Cell-bound Complement Activation Products in Combination with Low Complement C3 or C4 Have Superior Diagnostic Performance in Systemic Lupus Erythematosus
Sonali Narain¹, Daniel Wallace ², Chaim Putterman ³, Cristina Arriens ⁴, Anca Askanase ⁵, Kenneth Kalunian ⁶, Christopher Collins ⁷, Amit Saxena ⁸, Elena Massarotti ⁹, Roberta Alexander ¹⁰, Claudia Ibarra ¹⁰, Tyler O'Malley ¹¹, John Conklin ¹⁰, Rosalind Ramsey-Goldman ¹², Joseph Ahearn ¹³, Susan Manzi ¹³, Arthur Weinstein ¹⁰ and Thierry Dervieux ¹⁰, ¹Northwell Health, Great Neck, Long Island, NY, ²Cedars Sinai Medical Center/UCLA, Los Angeles, CA, ³Albert Einstein College of Medicine, New York, NY, ⁴Oklahoma Medical Research Foundation, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁵Columbia University, New York, ⁶Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, CA, ⁷MedStar Washington Hospital Center, Department of Rheumatology, Washington, DC, ⁸New York University School of Medicine, New York, NY, ⁹Brigham and Women's Hospital/Harvard Medical School, Boston, MA, ¹⁰Exagen, Vista, CA, ¹¹Exagen, Oceanside, CA, ¹²Northwestern University, Chicago, IL, ¹³Allegheny Health Network, Pittsburgh
Background/Purpose: Cell-bound complement activation products (CB-CAPs) are stable forms of classical complement activation ex-vivo, with high sensitivity and specificity for systemic lupus erythematosus (SLE). We…
Abstract Number: 692 • 2019 ACR/ARP Annual Meeting
Correlation of Urinary Soluble CD163 Levels with Clinicopathological Features in Lupus Nephritis: Its Role as a Potential Biomarker
Shilpa Venkataraman¹, Ankita Singh ², Manjula Murari ³, Vinita Agrawal ², Amita Aggarwal ³ and Rakesh Pandey ⁴, ¹Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India, ²Sanjay Gandhi Post Graduate institute of medical science, Lucknow, India, Lucknow, Uttar Pradesh, India, ³Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India, ⁴Sanjay Gandhi Postgraduate Institute for Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India
Background/Purpose: Lupus nephritis (LN), is seen in 30-50% patients with SLE and 5-10% patients progress to end-stage renal disease. The clinical disease activity indices do…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].